Ocera Therapeutics Company Profile (NASDAQ:OCRX)

Analyst Ratings

Consensus Ratings for Ocera Therapeutics (NASDAQ:OCRX) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.50 (279.06% upside)

Analysts' Ratings History for Ocera Therapeutics (NASDAQ:OCRX)
Show:
DateFirmActionRatingPrice TargetActions
4/12/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/6/2016Cowen and CompanyReiterated RatingBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2015Stifel NicolausLower Price TargetBuy$17.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Ocera Therapeutics (NASDAQ:OCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/1/2016        
4/29/2016Q1($0.33)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.33)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2015Q215($0.40)($0.46)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($0.29)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2015Q414($0.46)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q314($0.50)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q114($0.45)($0.46)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.43)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q413($0.21)($0.48)$2.93 million$52.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2013Q3 13($0.77)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocera Therapeutics (NASDAQ:OCRX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Ocera Therapeutics (NASDAQ:OCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ocera Therapeutics (NASDAQ:OCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/4/2016Linda S GraisCEOBuy3,000$3.19$9,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2016Linda S GraisCEOBuy10,000$2.38$23,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Gaurav AggarwalInsiderBuy10,000$2.15$21,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Michael ByrnesCFOBuy3,500$2.07$7,245.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015Wendall WierengaDirectorBuy5,000$3.71$18,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2015Rajiv PatniInsiderBuy5,050$3.97$20,048.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2015Gaurav AggarwalInsiderBuy7,500$3.62$27,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2015Linda S GraisCEOBuy30,000$3.73$111,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2015Michael ByrnesCFOBuy2,500$3.61$9,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Michael ByrnesVPBuy2,000$4.81$9,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/11/2014Linda S GraisCEOBuy10,000$5.93$59,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/11/2014Sharon TetlowCFOBuy3,000$5.83$17,490.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013Brian K HalakMajor ShareholderBuy995,618$6.03$6,003,576.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013Michael PowellDirectorBuy391,166$6.03$2,358,730.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ocera Therapeutics (NASDAQ:OCRX)
DateHeadline
07/05/16 12:08 PMETF’s with exposure to Ocera Therapeutics, Inc. : July 5, 2016 -
06/28/16 10:27 AMOcera Therapeutics Incorporated (NASDAQ:OCRX) Sellers Covered 21.23% of Their Shorts - Engelwood Daily
06/24/16 08:12 AMNew Broker Ratings For Ocera Therapeutics, Inc. (OCRX) - FTSE News
06/24/16 08:12 AMOcera Therapeutics Incorporated (NASDAQ:OCRX) Shorted Shares Decreased By 10.26% - Engelwood Daily
06/24/16 08:12 AMBrokers Issue Average Price Target Of 17.00 On Ocera Therapeutics, Inc. (OCRX) - Fiscal Standard
06/21/16 03:07 PMOCERA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure -
06/20/16 07:13 AMThis Weeks Broker Views For Ocera Therapeutics, Inc. (OCRX) - Fiscal Standard
06/15/16 04:30 PMOCERA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vo -
06/13/16 03:29 PMOcera to Present at the JMP Securities Life Sciences Conference - [at noodls] - PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., June 13, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan ...
06/08/16 01:25 PMETF’s with exposure to Ocera Therapeutics, Inc. : June 8, 2016 -
06/07/16 10:07 AMOcera Therapeutics, Inc. :OCRX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016 -
05/31/16 03:43 PMOcera to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., May 31, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan ...
05/26/16 03:17 PMOcera to Present at the 2016 BIO International Convention - [at noodls] - PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., May 26, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan ...
05/20/16 01:38 PMStocks Movements to Focus: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) , Ocera Therapeutics, Inc. (NASDAQ ... - Street Updates - Stocks Movements to Focus: Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) , Ocera Therapeutics, Inc. (NASDAQ ...Street UpdatesThe company has the institutional ownership of 53.50% while the Beta factor was 1.93. The stock's RSI amounts to 45.71. Ocera Therapeutics, Inc. (NASDAQ:OCRX) after beginning at $2.57, closed at $2.60 by cutting down +0.00% in recent trading session.and more »
05/03/16 07:16 AMThis Weeks Broker Price Targets For Ocera Therapeutics, Inc. (OCRX) - Share Trading News - This Weeks Broker Price Targets For Ocera Therapeutics, Inc. (OCRX)Share Trading NewsOcera Therapeutics, Inc. has a 50 day moving average of 3.00 and a 200 day moving average of 3.08. The stock's market capitalization is 59.87M, it has a 52-week low of 2.00 and a 52-week high of 4.80. The share price of the company (OCRX) was down ...and more »
05/02/16 07:43 AMOcera Therapeutics, Inc. (NASDAQ:OCRX) Boasts An Average Rating Of 2 - RealistInvestor.com - Ocera Therapeutics, Inc. (NASDAQ:OCRX) Boasts An Average Rating Of 2RealistInvestor.comAlpha One applies algorithm-based analytics for assessing a stock sentiment as per the published released on web channels. In this evaluation process, the group accesses the most relevant news platforms on a daily basis. Ocera Therapeutics, Inc.
05/02/16 07:43 AMACAD Gets FDA Nod, High-Five For ABBV's Imbruvica, NLNK Waits To Impress - NLNK closed Friday's trading at $16.21, up 2.08%. Ocera Therapeutics Inc.'s (OCRX) phase 2b study of OCR-002 in patients with acute hepatic encephalopathy has enrolled about 165 patients. The study, dubbed STOP-HE, is on target to complete enrollment in ...
04/30/16 07:38 AMLatest Analyst Ratings For Ocera Therapeutics, Inc. (OCRX) - Share Trading News - Web Breaking NewsLatest Analyst Ratings For Ocera Therapeutics, Inc. (OCRX)Share Trading NewsOcera Therapeutics, Inc. has a 50 day moving average of 3.03 and a 200 day moving average of 3.09. The stock's market capitalization is 61.92M, it has a 52-week low of 2.00 and a 52-week high of 4.80. The share price of the company (OCRX) was up ...Ocera Therapeutics Inc (OCRX) Announces Quarterly Earnings ResultsWeb Breaking NewsOcera Therapeutics, Inc. (NASDAQ:OCRX) Basic Consolidated EPS At $-1.3216Vanguard TribuneOcera Therapeutics Incorporated (NASDAQ:OCRX) Shorted Shares Increased By 4.22%Franklin IndependentNasdaqall 8 news articles »
04/30/16 07:38 AMOcera Therapeutics Inc.: Ocera Therapeutics Reports First Quarter 2016 Financial Results and Pipeline Progress - and RESEARCH TRIANGLE PARK, N.C., April 29, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today reported financial results for the quarter ...
04/29/16 08:05 AMOcera Therapeutics Reports First Quarter 2016 Financial Results and Pipeline Progress - [GlobeNewswire] - --Company on target to complete enrollment in STOP-HE in the fourth quarter; approximately 165 patients enrolled to date--. --Study with orally-available OCR-002 in patients with cirrhosis to begin in ...
04/25/16 08:24 AMOcera Therapeutics, Inc. (OCRX) Latest Broker Views - Risers & Fallers - Ocera Therapeutics, Inc. (OCRX) Latest Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Ocera Therapeutics, Inc. (OCRX). According to the latest broker reports outstanding on Monday 25th of April, 0 analysts have a rating of “strong buy”, 0 analysts “buy ...and more »
04/23/16 07:58 AMAnalyst Coverage: Ocera Therapeutics, Inc. (OCRX) - Risers & Fallers - Analyst Coverage: Ocera Therapeutics, Inc. (OCRX)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Ocera Therapeutics, Inc. (OCRX). The latest broker reports which are currently outstanding on Friday 22nd of April state 0 analysts have a rating of “strong buy”, 0 ...and more »
04/20/16 09:07 AMOcera Therapeutics, Inc. (OCRX) Updated Broker Price Targets - Share Trading News - Ocera Therapeutics, Inc. (OCRX) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Ocera Therapeutics, Inc. (OCRX). The latest reports which are currently in issue on Wednesday 20th of April state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
04/20/16 09:07 AMOcera Therapeutics: A Speculative Investment - Seeking Alpha - Seeking AlphaOcera Therapeutics: A Speculative InvestmentSeeking AlphaIn this article, we describe our investment thesis and valuation for Ocera Therapeutics (NASDAQ: OCRX), an emerging biopharmaceutical company based in Palo Alta, California. We are initiating coverage on Ocera Therapeutics with a speculative buy rating ...
04/15/16 11:41 AMOcera Therapeutics (OCRX) Will Present Preclinical Data from Two OCR-002 Studies at EASL - StreetInsider.com - Ocera Therapeutics (OCRX) Will Present Preclinical Data from Two OCR-002 Studies at EASLStreetInsider.comOcera Therapeutics, Inc. (Nasdaq: OCRX) announced that data from two investigator-sponsored preclinical studies of Ocera's ammonia scavenger, ornithine phenylacetate (OCR-002), will be presented today in poster sessions at The International Liver ...and more »
04/15/16 11:41 AMOcera Therapeutics Reports Presentation of Two Preclinical Studies Showing Further Support for OCR-002 - Ocera Therapeutics, Inc. (NASDAQ: OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that data from two investigator-sponsored preclinical studies of Ocera's ammonia scavenger, ornithine ...
04/15/16 11:41 AMOcera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia - and RESEARCH TRIANGLE PARK, N.C., April 15, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that data from two investigator ...
04/15/16 08:13 AMOcera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL) - [at noodls] - Data establish ammonia-lowering properties of orally-administered OCR-002 in preclinical model of cirrhosis Data highlight CNS neurochemical changes occurring in preclinical model of hepatic encephalopathy ...
04/15/16 08:08 AM9:08 am Ocera Therapeutics announces presentation of 2 pre-clinical studies 'further supporting' its ammonia scavenger OCR-002 at the International Liver Congress 2016 of the European Association for the study of the liver -
04/14/16 01:04 PMOcera Therapeutics Inc (OCRX) Earns Buy Rating from Brean Capital - Washington News Wire - Washington News WireOcera Therapeutics Inc (OCRX) Earns Buy Rating from Brean CapitalWashington News WireTurner Investments L.P. increased its position in shares of Ocera Therapeutics Inc (NASDAQ:OCRX) by 29.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 673,487 shares of the ...Ocera Therapeutics Inc (OCRX) Receives Buy Rating from Brean CapitalMas Market NewsCurrent Price Targets For Ocera Therapeutics, Inc. (OCRX)Risers & FallersOcera Therapeutics Incorporated (NASDAQ:OCRX) Shorted Shares Increased 2.05% After Market SellingSmallCapWired.comWeb Breaking Newsall 6 news articles »
04/13/16 01:42 PMCurrent Price Targets For Ocera Therapeutics, Inc. (OCRX) - Risers & Fallers - Current Price Targets For Ocera Therapeutics, Inc. (OCRX)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Ocera Therapeutics, Inc. (OCRX). The latest broker reports which are currently outstanding on Tuesday 12th of April state 2 analysts have a rating of “strong buy”, 2 ...and more »
04/12/16 11:41 AMOcera Therapeutics (OCRX) Reports Publication of Promising Preclinical Data Related to OCR-002 - StreetInsider.com - Ocera Therapeutics (OCRX) Reports Publication of Promising Preclinical Data Related to OCR-002StreetInsider.comOcera Therapeutics, Inc. (NASDAQ: OCRX)today announced the publication of promising preclinical data related to the Company's investigational drug candidate ornithine phenylacetate, OCR-002. The paper, entitled “Ammonia produces pathological ...Ocera Therapeutics Says Journal of Hepatology Publishes Encouraging Data on Lead Candidate (NASDAQ:OCRX)Sonoran Weekly Reviewall 2 news articles »
04/11/16 08:05 AMOcera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology - [GlobeNewswire] - PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., April 11, 2016-- Ocera Therapeutics, Inc., a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced ...
04/09/16 11:01 AMUpgrades And Downgrades For Ocera Therapeutics, Inc. (OCRX) - Risers & Fallers - Upgrades And Downgrades For Ocera Therapeutics, Inc. (OCRX)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Ocera Therapeutics, Inc. (OCRX). The latest broker reports which are currently outstanding on Friday 8th of April state 2 analysts have a rating of “strong buy”, 2 ...Ocera Therapeutics Incorporated (NASDAQ:OCRX) Short Interest Increased By 2.05%Clinton FinancialOcera Therapeutics Inc (NASDAQ:OCRX) Expected to Announce Earnings of -$0.33 Per ShareWeb Breaking NewsWhat Next for Ocera Therapeutics Inc Stock After Today's Huge Decline?Franklin Independentall 4 news articles »
04/07/16 07:40 PMETF’s with exposure to Ocera Therapeutics, Inc. : April 8, 2016 -
04/06/16 01:47 PMOcera Therapeutics, Inc. (OCRX) Updated Analyst Coverage - Risers & Fallers - Ocera Therapeutics, Inc. (OCRX) Updated Analyst CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Ocera Therapeutics, Inc. (OCRX). According to the latest broker reports outstanding on Tuesday 5th of April, 2 analysts have a rating of “strong buy”, 2 analysts “buy ...
04/06/16 01:47 PMQvt Financial Lp buys $2.7 Million stake in Ocera Therapeutics Inc (OCRX) - Everything HUDSON - Qvt Financial Lp buys $2.7 Million stake in Ocera Therapeutics Inc (OCRX)Everything HUDSONOcera Therapeutics Inc (OCRX) : Qvt Financial Lp scooped up 179,508 additional shares in Ocera Therapeutics Inc during the Q4 period, according to a recent disclosure to the SEC. The investment management firm now holds a total of 932,086 shares of ...
04/06/16 08:38 AMOcera Therapeutics, Inc. :OCRX-US: Earnings Analysis: 2015 By the Numbers -
04/05/16 03:47 PMOcera to Present at the 15th Annual Needham Healthcare Conference - [at noodls] - PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., April 05, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan ...
04/05/16 01:11 PMAfter Last Week What Do Analysts Think Of Ocera Therapeutics, Inc. (OCRX) - Share Trading News - After Last Week What Do Analysts Think Of Ocera Therapeutics, Inc. (OCRX)Share Trading NewsRecently some investment brokers have made changes to their outstanding price targets on shares of Ocera Therapeutics, Inc. (OCRX). According to data from Reuters, 2 analysts have a rating of “buy”, 2 analysts “outperform”, 0 analysts “hold”, 0 ...and more »
04/05/16 01:11 PMTurner Investments LP invests in 152210 by purchasing Ocera Therapeutics Inc (OCRX) shares - MicroCap Magazine - MicroCap MagazineTurner Investments LP invests in 152210 by purchasing Ocera Therapeutics Inc (OCRX) sharesMicroCap MagazineOcera Therapeutics logo Turner Investments L.P. boosted its stake in Ocera Therapeutics Inc (NASDAQ:OCRX) by 29.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 673,487 shares of the ...-$0.33 Earnings Per Share Expected for Ocera Therapeutics Inc (NASDAQ:OCRX) This QuarterFinancial Market NewsOcera Therapeutics Incorporated (NASDAQ:OCRX) Sellers Increased By 2.05% Their ShortsStock Callerall 4 news articles »
04/01/16 01:31 PMAnalyst Rating Changes For Ocera Therapeutics, Inc. (OCRX) - Share Trading News - Analyst Rating Changes For Ocera Therapeutics, Inc. (OCRX)Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Ocera Therapeutics, Inc. (OCRX). The latest reports which are currently in issue on Friday 1st of April state 2 analysts have a rating of “strong buy”, 2 analysts “buy ...
03/30/16 12:57 PMOcera Therapeutics (OCRX) Short Interest Disclosure - The Sussex Pilot - Ocera Therapeutics (OCRX) Short Interest DisclosureThe Sussex PilotInvestors should note that the Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged in a Form 4 filing that the CEO of Ocera Therapeutics, Inc., Grais Linda S had ...and more »
03/30/16 12:57 PMOcera Therapeutics, Inc. (OCRX) Updated Broker Ratings - Risers & Fallers - Ocera Therapeutics, Inc. (OCRX) Updated Broker RatingsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Ocera Therapeutics, Inc. (OCRX). According to the latest broker reports outstanding on Wednesday 30th of March, 2 analysts have a rating of “strong buy”, 2 analysts ...and more »
03/24/16 08:58 AMLifeSci Capital Initiates Coverage of Ocera Therapeutics - [Accesswire] - Developing Therapies for Serious Diseases with High Unmet Medical Need; Report Available Here: http://www.lifescicapital.com/equity-research/ocera/ NEW YORK, NY / ACCESSWIRE / March 24, 2016 / LifeSci ...
03/20/16 01:19 PMOcera Therapeutics, Inc. (OCRX): Analyst Targets For The Coming Week - Share Trading News - Ocera Therapeutics, Inc. (OCRX): Analyst Targets For The Coming WeekShare Trading NewsRecently some investment brokers have made changes to their outstanding price targets on shares of Ocera Therapeutics, Inc. (OCRX). According to data from Reuters, 2 analysts have a rating of “buy”, 2 analysts “outperform”, 0 analysts “hold”, 0 ...and more »
03/17/16 12:04 PMOCERA THERAPEUTICS, INC. Financials -
03/11/16 03:17 PMOCERA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report -
03/10/16 12:25 PMOcera Therapeutics, Inc. (OCRX) New Analyst Updates - Risers & Fallers - Ocera Therapeutics, Inc. (OCRX) New Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Ocera Therapeutics, Inc. (OCRX). According to the latest broker reports outstanding on Wednesday 9th of March, 2 analysts have a rating of “strong buy”, 2 analysts ...and more »
03/09/16 01:31 PMExpected Increase of Profit for Ocera Therapeutics Inc (OCRX) - OctaFinance.com - Expected Increase of Profit for Ocera Therapeutics Inc (OCRX)OctaFinance.comAnalysts await Ocera Therapeutics Inc (NASDAQ:OCRX) to reports earnings on March, 9. They expect $-0.31 earnings per share, down 10.71 % or $0.03 from last year's $-0.28 per share. After $-0.34 actual earnings per share reported by Ocera Therapeutics ...The Profit of Ocera Therapeutics Inc (OCRX) Expected to RiseFranklin IndependentOcera Therapeutics, Inc. (OCRX) Files Form 4 Insider Buying : Linda S Grais Buys 3000 SharesSCSUCollegianIs Ocera Therapeutics Inc a Buy? The Stock Rises AgainStock CallerEquities.comall 8 news articles »

Social

About Ocera Therapeutics

Ocera Therapeutics logoOcera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OCRX
  • CUSIP:
Key Metrics:
  • Previous Close: $2.77
  • 50 Day Moving Average: $2.39
  • 200 Day Moving Average: $2.72
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $59.02M
  • Beta: 2.18
  • Current Year EPS Consensus Estimate: $-1.43 EPS
  • Next Year EPS Consensus Estimate: $-1.44 EPS
Additional Links:
Ocera Therapeutics (NASDAQ:OCRX) Chart for Tuesday, July, 26, 2016